SL
GMAB icon

Summitry LLC’s Genmab GMAB Stock Holding History

Summitry LLC’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$309K Buy
11,249
+79
+0.7% +$2.1K 0.01% 238
2026
Q1 		$300K Buy
11,170
+567
+5% +$17K 0.01% 211
2025
Q4 		$327K Buy
10,603
+3,465
+49% +$108K 0.01% 169
2025
Q3 		$219K Buy
+7,138
New +$174K 0.01% 200

Other funds holding GMAB

PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Summitry LLC's GMAB Position: Q2 2026 in Review

Summitry LLC increased its Genmab (GMAB) stake by 0.71% in Q2 2026, buying an estimated $2.1K and bringing the position to 11,249 shares worth $309K. The position accounts for 0.01% of the portfolio, ranked #238.

Summitry LLC first reported a position in GMAB in Q3 2025 and has held it in 4 quarters since. The position peaked at $327K in Q4 2025. 289 funds tracked by Wall St. Rank hold GMAB as of Q2 2026.

  • Summitry LLC held 11,249 shares of Genmab worth $309K as of Q2 2026.
  • Summitry LLC bought 79 Genmab shares in Q2 2026, an estimated $2.1K.
  • Genmab made up 0.01% of Summitry LLC's portfolio in Q2 2026, its #238 holding.
  • Summitry LLC first reported a position in Genmab in Q3 2025 and has held it in 4 quarters since.
  • Summitry LLC's Genmab position peaked at $327K in Q4 2025.
  • 289 funds tracked by Wall St. Rank held Genmab as of Q2 2026.

Based on Summitry LLC's 13F filing for Q2 2026, filed 21 Jul 2026.